Scholay

学术搜索 · AI 审稿 · LaTeX 协作

Long Term Nucleos(t)ide Analog Therapy after Immunglobuline Withdrawal in Liver Transplant Recipients to Prevent Recurrent Hepatitis B

作者:Carmelo Loinaz, Inmaculada Fernández, Óscar Caso, Olga Hernández, M. Abradelo, Marisa Manzano, F. Cambra, Álvaro García‐Sesma, Jorge Calvo, Iago Justo, Alejandro Manrique, Alberto Marcacuzco, Carlos María Gómez-Centurión Jiménez, Gregorio Castellano · 发表于:Transplantation · 年份:2018 · DOI:10.1097/01.tp.0000542733.57512.fd · 研究领域:Hepatitis B Virus Studies、Hepatitis C virus research、Hepatitis Viruses Studies and Epidemiology

Introduction Prophylaxis of hepatitis B virus (HBV) recurrence after liver transplantation (LT) has been based on hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analog (NA). Combining both agents is the most usual approach in Europe, and there is little experience on HBIG withdrawal and sole NA prophylaxis in our area. We show our approach since 2011 evaluating the efficay and safety of entecavir (ETV) or tenofovir disiproxil fumarate (TDF) after discontinuation of HBIG in LT patients treated with HBIG since the operation. Materials and Methods Eligible for HBIG withdrawal were patients at low or intermediate risk of recurrence (fulminant HBV hepatitis, D virus coinfection, HBeAg negative cirrhotic patients with HBV DNA levels <300 copies/ml). After discontinuation they had ETV or TDF monotherrapy. Clinical (general condition and renal function) and laboratory follow-up (serum HBV markers) was conducted. Results Between 09-2011 and 06-2014, 58 LT recipients were converte to TDF (31, 53%) or ETV (27, 47%). All had received HBIG for at least 12 months after LT (mean 108.4 +/- 60.7 months, range 18-257), with or without NA. Mean follow-up after conversion was 65.2 +/- 9.5 months (range 13-75), including 3 patients that died of HBV unrelated causes, at 13, 44 and 45 months. Five patients (8.6%) developed transient detectable HBV surface antigen (HBsAg) at 7, 9, 13, 15 and 22 months after HBIG discontinuation, with undetectable HBV DNA, without clinical manifestations or recu...